1
项与 CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai) 相关的临床试验 / Not yet recruiting临床1期IIT A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This is a single-arm, open-label, phase I dose-escalation clinical study to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual-target CAR T cell injection in r/r AML subjects.
100 项与 CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai) 相关的临床结果
100 项与 CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai) 相关的转化医学
100 项与 CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai) 相关的专利(医药)
100 项与 CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai) 相关的药物交易